Insider buying · SEC Form 4

Insider Buying — Jul 2, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

2insider buys
$1.17Mbought in total
1company
1by CEOs, CFOs and other chiefs
NVCTlargest: $916K

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
NVCTNuvectis Pharma, Inc.Marlio Charles Mosseri10% Owner$916K50,000$18.32AddedJul 1, 2026
Form 4 ↗
Bought 50,000 shares at weighted avg $18.32 on June 30 (ranging $18.29–$18.32), one day before the company's $100M public offering closed at $20/share. True open-market purchase below offering price. Serial accumulator: 25 buys, 0 sells over 5 years. Now $19.52 (+6.5% since buy).
NVCTNuvectis Pharma, Inc.Ron BentsurChairman & CEO$250K12,500$20.00AddedJul 1, 2026
Form 4 ↗
Bought 12,500 shares at $20.00/share on June 30 — exactly the public offering price announced June 29. Likely directed-share participation in the $100M offering, not pure open-market. CEO commitment buy alongside the deal. Now $19.52 (−2.4% since buy). Post-transaction holdings: 3,688,424 shares.

AIThe day in insider buying

SEC Form 4 Insider Scan — July 2, 2026

Scanned the last 24 hours of EDGAR Form 4 filings (filed July 1–2, 2026). 2 qualifying buys (≥ $250K, transaction type P) totalling $1.17M.

Data note: Direct EDGAR / aggregator endpoints (sec.gov, efts.sec.gov, openinsider.com, finviz.com) are blocked by the session egress policy. Data sourced from web-search snippets via Quiver Quantitative, StockTitan, Investing.com, and Globe Newswire; NVCT spot from Tradier fetch_quote.

Headline filings

  • NVCT — Marlio Charles Mosseri (10% Owner) bought 50,000 shares ≈ $916K at $18.32 avg (June 30, filed July 1); now $19.52 (+6.5% since buy). Mosseri is a serial NVCT accumulator — 25 buys, 0 sells over 5 years. Purchased on the open market one day ahead of the company's $100M public offering closing at $20, signalling conviction at a discount to the deal price. (EDGAR filings)
  • NVCT — Ron Bentsur (Chairman & CEO) bought 12,500 shares ≈ $250K at $20.00 (June 30, filed July 1); now $19.52 (−2.4% since buy). Purchase price matches the offering price exactly — likely a directed-share participation in the same $100M offering announced June 29. CEO skin-in-the-game alongside the deal. (EDGAR filings)

Notes

Single-stock cluster: Both qualifying buys are in Nuvectis Pharma (NVCT), a ~$160M-market-cap oncology biotech. The company priced a $100M public offering on June 29 at $20/share (closing July 1). A 10% owner buying 50K shares below the offering price on the open market the day before closing is the more meaningful signal — Mosseri appears to be adding ahead of expected catalysts. The CEO's co-purchase at the offering price rounds out insider commitment.

Other July 1 P-coded filings scanned but below the $250K threshold: Polestar (PSNY) director 6,000 ADSs (~$102K), Hyperscale Data (GPUS) CEO 5,000 preferred shares (~$95K), Simon Property Group (SPG) directors 508–508 shares each (~$114K per transaction), Casey's General Stores (CASY) director 256 shares (~$199K), SWZ director 4,091 shares (~$24K).

Biotech / small-cap focus: The $250K+ bar filtered most routine accumulator purchases at larger-cap names. No large-cap CEO discretionary buys identified in this 24-hour window.

Most-bought stocks, last 30 days

  • HOOD $65.5M · 4 buysRobinhood Markets, Inc.
  • NCLH $25.0M · 1 buyNorwegian Cruise Line Holdings Ltd.
  • NSP $23.8M · 3 buysInsperity Inc.
  • ARTV $16.6M · 3 buys, 3 insidersArtiva Biotherapeutics Inc.
  • TXO $16.5M · 2 buysTXO Partners, L.P.
  • AVO $14.4M · 6 buys, 3 insidersMission Produce Inc
  • PBLS $10.2M · 2 buys, 2 insidersParabilis Medicines, Inc.
  • STEP $10.0M · 2 buysStepStone Group Inc.
  • PSEC $9.35M · 3 buys, 2 insidersProspect Capital Corp
  • MNSO $6.90M · 1 buyMINISO Group Holding Limited
  • FUN $5.90M · 1 buySix Flags Entertainment Corporation
  • LODE $4.35M · 3 buys, 3 insidersComstock Inc.
  • SMMT $3.64M · 3 buys, 3 insidersSummit Therapeutics Inc.
  • COE $3.25M · 1 buy51Talk Online Education Group
  • FISV $3.25M · 7 buys, 4 insidersFiserv Inc.
  • AII $2.30M · 1 buyAmerican Integrity Insurance Group, Inc.
  • FCNCA $2.04M · 2 buysFirst Citizens BancShares Inc.
  • AMR $2.01M · 1 buyAlpha Metallurgical Resources Inc.
  • GPGI $1.99M · 2 buysGPGI, Inc.
  • NXST $1.99M · 1 buyNexstar Media Group, Inc.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.